As reported on BioPharmaDive, new clinical trial data presented at the American Society of Hematology (ASH) annual meeting suggests that an early treatment regimen combining Tecvayli (Johnson & Johnson’s bispecific antibody) with Darzalex could significantly improve outcomes for patients with multiple myeloma, and may even offer curative potential.
Key Findings from the MajesTEC-3 Trial
The MajesTEC-3 study evaluated Tecvayli plus Darzalex against a standard regimen of Darzalex combined with other therapies in patients who had experienced disease progression after one to three prior treatments. Results were striking:
- Risk Reduction: The Tecvayli-Darzalex combination reduced the relative risk of disease progression or death by 83% compared to the control group.
- Durable Responses: Among patients who remained relapse-free for six months, 90% were still progression-free at three years.
- Complete Response Rates: 82% of patients receiving the combination achieved complete response (no detectable disease), versus 32% in the comparator arm.
- Overall Survival: Three-year survival was 83% for the Tecvayli group, compared to 65% for those on standard therapy.
These outcomes led investigators to suggest that early use of bispecific antibodies could transform treatment paradigms for multiple myeloma.
Why Earlier Use Matters
Currently, bispecific antibodies like Tecvayli are approved only for patients who have undergone at least four prior lines of therapy. Experts believe moving these agents earlier in the disease course could dramatically improve efficacy. As Dr. Amrita Krishnan of City of Hope noted, “Giving bispecific antibodies earlier works better, and combining them with Darzalex further enhances their effect.”
Comparison to CAR-T Therapy
Tecvayli may offer a more accessible alternative to CAR-T cell therapy, which requires complex manufacturing and is typically limited to specialized centers. Bispecific antibodies, by contrast, can be administered in community oncology settings, expanding access for patients who may not be candidates for CAR-T.
Safety Considerations
While efficacy was impressive, infection risk remains a concern. In the Tecvayli-Darzalex arm, 13 patients died from infections, and higher rates of COVID-19, pneumonia, and other respiratory illnesses were observed. Investigators implemented preventive measures such as immunoglobulin replacement and antimicrobial prophylaxis, but vigilance will be critical as these therapies move into broader use.
Implications for Practice
Johnson & Johnson aims to make bispecific antibodies available earlier in treatment, particularly for patients treated in community settings. If approved for earlier use, Tecvayli could become a cornerstone therapy, offering convenience and potentially long-term remission for many patients.
